Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

neoantigen srRNA vaccine JCXH-212

A cancer vaccine consisting of self-replicating RNA (srRNA) encoding a patient's tumor-specific neoantigens, with potential immunomodulatory and antineoplastic activities. Upon administration of neoantigen srRNA vaccine JCXH-212, the srRNA is taken up by and translated into the neoantigens in the patient's antigen-presenting cells (APCs), primarily dendritic cells (DCs), and presented by major histocompatibility complex (MHC) molecules on the surface of the APCs. This may activate tumor antigen-specific T-cells to kill cancer cells expressing these neoantigens.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	vaccine JCXH-212
Code name:	JCXH 212 JCXH-212 JCXH212

neoantigen srRNA vaccine JCXH-212

Search NCI's Drug Dictionary